Respiratory syncytial virus (RSV) has become an important consideration for healthcare providers managing respiratory infections, particularly among infants, older adults and people with underlying medical vulnerabilities. Its symptoms frequently resemble influenza and pandemic, making clinical identification difficult without laboratory confirmation. This overlap has increased the importance of reliable diagnostic methods that can distinguish between multiple respiratory pathogens.
The clinical significance extends beyond paediatric hospitals. Emergency departments, outpatient clinics, intensive care units and long-term care facilities increasingly require diagnostic systems that can deliver actionable results within the patient-care window. In 2026, RSV testing is consequently gaining greater attention as healthcare systems strengthen their respiratory infection identification capabilities.
Molecular Testing Is Setting New Expectations for Diagnostic Accuracy
Reverse transcription polymerase chain reaction (RT-PCR) and other nucleic acid amplification tests (NAATs) remain important technologies for RSV identification. Their ability to detect viral genetic material makes them particularly valuable when symptoms are unclear or viral concentrations are relatively low.
The CDC updated its RSV diagnostic testing guidance on February 24, 2026, highlighting the high sensitivity of molecular testing compared with antigen-based approaches. Antigen tests nevertheless retain clinical relevance because they can provide quicker results in appropriate settings.
Another important development is the availability of assays capable of distinguishing RSV subtypes A and B. Although the clinical significance of subtype differentiation remains uncertain, this capability contributes to laboratory surveillance and research activities.
Multiplex Respiratory Panels Are Changing Hospital Testing Workflows
Hospitals are increasingly interested in diagnostic platforms that identify several respiratory infections from a single patient specimen. Multiplex testing can simultaneously detect RSV, influenza A, influenza B and SARS-CoV-2, helping clinicians distinguish infections with overlapping symptoms.
In August 2025, Roche announced FDA clearance for its cobas Respiratory 4-flex assay, which uses its TAGS technology to identify these four respiratory viruses on the cobas 5800, 6800 and 8800 systems.
This development illustrates how diagnostic manufacturers are moving toward flexible syndromic testing platforms. For laboratories processing substantial respiratory specimen volumes, consolidated testing can simplify workflows and reduce the need for separate diagnostic procedures.
Point-of-Care Diagnostics Are Bringing Laboratory Capabilities Closer to Patients
The growing availability of near-patient molecular testing is changing where respiratory infections can be identified. Instead of depending entirely on centralized laboratories, healthcare providers can increasingly access diagnostic results within outpatient clinics, urgent care facilities and emergency departments.
Abbott's ID NOW RSV platform, for example, provides molecular results in approximately 13 minutes or less. Similarly, DiaSorin received FDA clearance and a CLIA waiver in December 2025 for its LIAISON NES four-pathogen respiratory panel, designed to deliver results in approximately 15 minutes.
These developments demonstrate the commercial and clinical relevance of compact diagnostic platforms, particularly where rapid identification can influence patient management and infection-control decisions.
Home-Based Respiratory Testing Is Opening another Healthcare Segment
Respiratory diagnostics are gradually extending beyond conventional hospital and laboratory environments. At-home testing offers another route for identifying respiratory infections, especially when patients seek preliminary information without immediately visiting a healthcare facility.
The introduction of multi-pathogen home-testing products, including tests covering RSV, influenza and COVID-19, demonstrates this changing accessibility. However, test sensitivity, age-specific suitability and instructions for interpreting negative results remain important considerations.
For manufacturers, this creates opportunities to develop convenient testing formats supported by clear clinical guidance, reliable specimen collection and appropriate regulatory authorization.
RSV Surveillance Is Increasing the Importance of Laboratory Connectivity
Diagnostic testing also contributes to public health monitoring. Identifying RSV infections helps healthcare authorities understand seasonal circulation, monitor outbreaks and evaluate changes in respiratory disease activity.
The World Health Organization's respiratory virus surveillance activities emphasize integrated laboratory approaches. Its October 2026 guidance on laboratory testing algorithms also highlights the importance of flexible surveillance strategies and avoiding missed RSV detection when testing is restricted to specimens negative for other respiratory viruses.
This creates additional relevance for laboratories with molecular testing, specimen storage and genomic surveillance capabilities.
What Diagnostic Manufacturers Need to Address Next?
The next stage of RSV diagnostic development will depend on balancing analytical sensitivity, testing speed, affordability and accessibility. Manufacturers are exploring improvements in sample preparation, automated result interpretation, multiplex detection and decentralized testing.
Equally important are specimen quality, instrument compatibility, quality-control procedures and external performance evaluation. Healthcare providers need diagnostic systems that perform consistently across different patient populations and clinical environments.
As respiratory testing becomes more integrated into routine healthcare, RSV diagnostics will increasingly be evaluated not simply by their ability to detect a virus, but by how effectively they support timely clinical decisions, hospital workflows and public health preparedness.
Authoritative Sources and Further Reading
CDC - Diagnostic Testing for RSV (2026).
CDC - Multiplex Tests to Detect Influenza, SARS-CoV-2 and RSV.
CDC - Clinical Guidance for Co-Circulating Respiratory Viruses.
